Abstract

Bacterial ribosome rescue pathways that remove ribosomes stalled on mRNAs during translation have been proposed as novel antibiotic targets because they are essential in bacteria and are not conserved in humans. We previously reported the discovery of a family of acylaminooxadiazoles that selectively inhibit trans-translation, the main ribosome rescue pathway in bacteria. Here, we report optimization of the pharmacokinetic and antibiotic properties of the acylaminooxadiazoles, producing MBX-4132, which clears multiple-drug resistant Neisseria gonorrhoeae infection in mice after a single oral dose. Single particle cryogenic-EM studies of non-stop ribosomes show that acylaminooxadiazoles bind to a unique site near the peptidyl-transfer center and significantly alter the conformation of ribosomal protein bL27, suggesting a novel mechanism for specific inhibition of trans-translation by these molecules. These results show that trans-translation is a viable therapeutic target and reveal a new conformation within the bacterial ribosome that may be critical for ribosome rescue pathways.

Antibiotic-resistant bacterial pathogens pose a substantial threat to human health. Here, aided by structural analyses, the authors describe the molecular mechanism behind the activity of a series of compounds that inhibit trans-translation and are effective in eradicating N. gonorrhoeae infection in mice.

Details

Title
trans-Translation inhibitors bind to a novel site on the ribosome and clear Neisseria gonorrhoeae in vivo
Author
Aron, Zachary D 1 ; Mehrani Atousa 2 ; Hoffer, Eric D 3 ; Connolly, Kristie L 4   VIAFID ORCID Logo  ; Srinivas Pooja 5 ; Torhan, Matthew C 1 ; Alumasa, John N 6   VIAFID ORCID Logo  ; Cabrera Mynthia 6 ; Hosangadi Divya 6 ; Barbor, Jay S 1 ; Cardinale, Steven C 1 ; Kwasny, Steven M 1 ; Morin, Lucas R 1   VIAFID ORCID Logo  ; Butler, Michelle M 1 ; Opperman, Timothy J 1 ; Bowlin, Terry L 1 ; Jerse, Ann 4 ; Stagg, Scott M 7   VIAFID ORCID Logo  ; Dunham, Christine M 3   VIAFID ORCID Logo  ; Keiler, Kenneth C 6   VIAFID ORCID Logo 

 Microbiotix, Inc. One Innovation Dr., Worcester, USA (GRID:grid.280642.a) (ISNI:0000 0004 1796 7154) 
 Florida State University, Department of Chemistry and Biochemistry, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419) 
 Emory University School of Medicine, Department of Biochemistry and Emory Antibiotic Resistance Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Uniformed Services University, Department of Microbiology and Immunology, Bethesda, USA (GRID:grid.265436.0) (ISNI:0000 0001 0421 5525) 
 Emory University School of Medicine, Department of Biochemistry and Emory Antibiotic Resistance Center, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University, Molecular & Systems Pharmacology Graduate Program, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Penn State University, Department of Biochemistry & Molecular Biology, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281) 
 Florida State University, Department of Chemistry and Biochemistry, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419); Florida State University, Institute of Molecular Biophysics, Tallahassee, USA (GRID:grid.255986.5) (ISNI:0000 0004 0472 0419) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2503047347
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.